Free Trial
NASDAQ:ACRV

Acrivon Therapeutics (ACRV) Stock Price, News & Analysis

Acrivon Therapeutics logo
$8.01
+0.01 (+0.13%)
(As of 11/1/2024 ET)

About Acrivon Therapeutics Stock (NASDAQ:ACRV)

Key Stats

Today's Range
$7.92
$8.13
50-Day Range
$6.89
$9.98
52-Week Range
$3.19
$11.90
Volume
35,926 shs
Average Volume
294,123 shs
Market Capitalization
$248.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.83
Consensus Rating
Buy

Company Overview

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Acrivon Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
68th Percentile Overall Score

ACRV MarketRank™: 

Acrivon Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 361st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Acrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Acrivon Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Acrivon Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.40) to ($2.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Acrivon Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Acrivon Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Acrivon Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Acrivon Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.11% of the float of Acrivon Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Acrivon Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Acrivon Therapeutics has recently decreased by 8.26%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Acrivon Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Acrivon Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.11% of the float of Acrivon Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Acrivon Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Acrivon Therapeutics has recently decreased by 8.26%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Acrivon Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Acrivon Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for ACRV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.50% of the stock of Acrivon Therapeutics is held by insiders.

  • Percentage Held by Institutions

    71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Acrivon Therapeutics' insider trading history.
Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRV Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

ACRV Stock Analysis - Frequently Asked Questions

Acrivon Therapeutics' stock was trading at $4.92 at the start of the year. Since then, ACRV stock has increased by 62.8% and is now trading at $8.01.
View the best growth stocks for 2024 here
.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.08.

Acrivon Therapeutics (ACRV) raised $100 million in an IPO on Tuesday, November 15th 2022. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO.

Acrivon Therapeutics' top institutional investors include Exchange Traded Concepts LLC (0.07%). Insiders that own company stock include Perceptive Advisors Llc, Ra Capital Management, LP and Ltd Chione.
View institutional ownership trends
.

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

Last Earnings
8/13/2024
Today
11/02/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACRV
Fax
N/A
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.83
High Stock Price Target
$30.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+197.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-60,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.38 per share

Miscellaneous

Free Float
28,339,000
Market Cap
$248.07 million
Optionable
Not Optionable
Beta
0.78
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ACRV) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners